Leveraging our leading regenerative medicine technologies has led us to develop breakthrough applications in the field of oral soft tissue regeneration. We have completed Phase III testing of CelTx™ and filed an application for CelTx™ with the FDA in 2009.
For additional information, please contact the Organogenesis Medical Information Center.
